Did you know?
ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.
Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!
Five China Pharmas to Supply Generic COVID-19 Therapy to Low Income Countries
The five pharmaceutical companies are Zhejiang Huahai Pharma, Apeloa Pharma,
Yifang Wu, Chairman and CEO of Fosun Pharma said that the company is pleased to reach an agreement with the MPP to help supply global access to COVID-19 medicines. "Fosun Pharma is committed to improving the accessibility of COVID-19 drugs in low-income countries and will continue to make contributions to global efforts to combat the disease," Wu said in a statement.
The MPP license from Pfizer aims to provide new medicines such as nirmatrelvir as soon as possible at affordable prices in low- and middle-income countries. The non-exclusive sublicense will allow generic manufacturers to produce the raw ingredients for nirmatrelvir and/or the finished drug itself, co-packaged with ritonavir, according to the MPP.